Literature DB >> 18551260

[Postoperative pain management. Application of an iontophoretic patient-activated transdermal system].

S Grond1, J Jage, H Van Aken.   

Abstract

Intravenous patient-controlled analgesia (i.v. PCA) for parenteral postoperative pain control is considered standard therapy as patients can individually titrate the amount of analgesic as needed. Iontophoretic patient-activated transdermal systems (IPATS) are a new non-invasive pre-programmed method for postoperative pain control. By pressing the dosing button a 40 microg dose of fentanyl is delivered over a 10 min period via iontophoresis through the intact skin. Several comparative randomized controlled trials have demonstrated that IPATS provide postoperative pain control equivalent to i.v. PCA with morphine. Thus, IPATS is a new method in the management of acute postoperative pain which increases patient mobility and reduces time and effort of care as well as the risk of programming errors. In this review the efficacy, pharmacokinetics, handling and process cost-effectiveness of IPATS are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551260     DOI: 10.1007/s00101-008-1369-z

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  26 in total

1.  The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS).

Authors:  Gayatri Sathyan; Katayoun Zomorodi; Shalini Gidwani; Suneel Gupta
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Transdermal iontophoresis.

Authors:  Priya Batheja; Batheja Priya; Rashmi Thakur; Thakur Rashmi; Bozena Michniak; Michniak Bozena
Journal:  Expert Opin Drug Deliv       Date:  2006-01       Impact factor: 6.648

3.  Programming errors contribute to death from patient-controlled analgesia: case report and estimate of probability.

Authors:  Kim J Vicente; Karima Kada-Bekhaled; Gillian Hillel; Andrea Cassano; Beverley A Orser
Journal:  Can J Anaesth       Date:  2003-04       Impact factor: 5.063

4.  [Postoperative pain relief is an important factor for the patients' selection of a clinic. Results of an anonymous survey].

Authors:  C Simanski; R Lefering; T Paffrath; P Riess; N Yücel; M Maegele; C Thüsing; E Neugebauer
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

Review 5.  Patient-controlled analgesia: An efficient therapeutic tool in the postoperative setting.

Authors:  K A Lehmann
Journal:  Eur Surg Res       Date:  1999       Impact factor: 1.745

Review 6.  Patient-controlled analgesia.

Authors:  R C Etches
Journal:  Surg Clin North Am       Date:  1999-04       Impact factor: 2.741

Review 7.  An iontophoretic, fentanyl HCl patient-controlled transdermal system for acute postoperative pain management.

Authors:  Jacques E Chelly
Journal:  Expert Opin Pharmacother       Date:  2005-06       Impact factor: 3.889

8.  Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia.

Authors:  Craig T Hartrick; Michael H Bourne; Kathryn Gargiulo; C V Damaraju; Sue Vallow; David J Hewitt
Journal:  Reg Anesth Pain Med       Date:  2006 Nov-Dec       Impact factor: 6.288

9.  The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies.

Authors:  Eugene R Viscusi; Matthew Siccardi; C V Damaraju; David J Hewitt; Paul Kershaw
Journal:  Anesth Analg       Date:  2007-11       Impact factor: 5.108

10.  Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management.

Authors:  S Grond; J Hall; A Spacek; M Hoppenbrouwers; U Richarz; F Bonnet
Journal:  Br J Anaesth       Date:  2007-06       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.